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INTRODUCTION
Esthesioneuroblastoma (olfactory neuroblastoma) is a rare si-
nonasal tumor originating from the olfactory neuroepitheli-
um. Ectopic adrenocorticotropic hormone (ACTH) syndrome 
is defined as an abnormal elevation of plasma ACTH secreted 
from a source other than a pituitary or an adrenal gland.1 New 
technology that uses radiolabeled somatostatin analogs, such 
as 68Ga-DOTA-conjugated positron emission tomography 
(PET), is useful in detecting an unidentified ectopic ACTH-
producing neuroendocrine tumor.2 Here, we report a case of 




A 46-year-old man without significant medical history present-
ed with hyposmia and Cushingoid feature. On laboratory test, 
hypokalemia (2.6 mmol/L) was identified, and serum cortisol 
and plasma ACTH levels were 70.1 mcg/dL and 291.4 pg/mL, 
respectively. A profound increase in 24-h urine cortisol (7665 
mcg/day) was also confirmed. Renin and aldosterone were 
within the normal range and ratio, which excluded primary 
hyperaldosteronism. In both low-dose and high-dose dexa-
methasone suppression test (DMST), cortisol was not suffi-
ciently suppressed, which is suggestive of ectopic Cushing’s 
disease, and the result of inferior petrosal sinus sampling (IPSS) 
was consistent with Cushing’s disease. Sellar MRI (Achieva; 
Philips, Best, Netherlands) showed no pituitary enlargement 
or tumor and, instead, revealed a bulky mass in nasal cavity 
(Fig. 1A and B). Due to diagnostic uncertainty on the source of 
ACTH secretion, we conducted nuclear imaging with a soma-
tostatin analog tracer. The 68Gallium-DOTA-TOC PET scan 
showed strong uptake in the nasal cavity (Fig. 1C). Preopera-
tive clinical characteristics are summarized in Table 1. In-
formed consent was obtained from the patient for this report.
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ectopic Cushing’s syndrome, the tumor was surgically resect-
ed. First, the intranasal portion of the tumor was removed by 
an endoscopic endonasal approach (Supplementary Video 1 
only online). The tumor was very soft and hypervascular. We 
then performed transcranial tumor removal via a bifrontal cra-
niotomy and an extradural approach. The tumor was radically 
removed together with surrounding dural layer and the ante-
rior skull base. The galeal flap was harvested and used to cover 
the skull defect. From the nasal cavity, the skull defect was cov-
ered by a nasoseptal flap. Lumbar puncture was maintained 
until 13 days after surgery. After the surgery, the patient was 
closely monitored in the intensive care unit with regular mea-
surement of serum ACTH, cortisol, and 24-h urinary free corti-
sol levels.
Histopathological findings
The histopathological diagnosis was that of an esthesioneuro-
blastoma with Hyams grade I (Fig. 2A). Immunohistochemi-
cal staining for ACTH was positive (Fig. 2B). The stains for neu-
ron-specific enolase, synaptophysin, and chromogranin A, 
which are suggestive of neuroendocrine features, were positive 
(Fig. 2C and D). Anti T-Pit stain, a reliable corticotroph marker, 
was negative and disfavored an ectopic ACTH-secreting pitu-
itary adenoma (Fig. 2E). Taken together, the histopathological 
findings were consistent with ACTH-secreting esthesioneuro-
blastoma.
Postoperative course
The serum levels of both cortisol and ACTH rapidly dropped to 
Fig. 1. Preoperative magnetic resonance imaging (MRI) and 68Ga-DOTA-congugated octreotide positron emission tomography (PET)/computed tomography 
(CT) scan. Axial and sagittal views of T1-weighted post-contrast MRI show a heterogeneously enhanced mass in the nasal cavity, sphenoid sinus, and fron-
tal base (A and B). 68Ga-DOTA-congugated octreotide PET/CT scan reveals high somatostatin uptake in the tumor, which is suggestive of a neuroendocrine 
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7.3 mcg/dL and 26.94 pg/mL at 12 hours after surgery and to 
17.9 mcg/dL and less than 0.1 pg/mL on postoperative day 3. 
No remnant tumor was identified in 24-h postoperative brain 
MRI. After 1 month, the patient underwent adjuvant radio-
therapy (total 55 Gy in 25 fractions). 12-month postoperative 
MRIs showed no recurrence (Fig. 1D). DMST results and 24-h 
urine free cortisol levels were all normal at 3 months after sur-
gery. Serum cortisol and plasma ACTH levels were 8.4 mcg/dL 
and 40.00 pg/mL, respectively, at 12 months after surgery. To 
date, the patient is uneventful.
Table 1. Preoperative endocrinological and radiological evaluation
Study Results
Basal hormone test
Serum cortisol 70.1 mcg/dL (reference: 6–23 mcg/dL)
Plasma ACTH 291.4 pg/mL (reference: 7.2–63.3 pg/mL)
24 hr-urine cortisol 7665 mcg/day (reference: 58.00–403.00 mcg/day)
Low-dose DMST
Not suppressed
Serum cortisol 39.9 mcg/dL, Plasma ACTH 218.90 pg/mL 
High-dose DMST
Not suppressed
Serum cortisol 34.8 mcg/dL, Plasma ACTH 159.10 pg/mL
IPSS
Left inferior petrosal sinus dominant
Basal inferior petrosal sinus/peripheral 2.4 (Reference: >2.0)
Sellar dynamic MRI
No evidence of pituitary adenoma
Tumor in the sinonasal cavity with intracranial and intraorbital extension
68Gallium-DOTA-TOC PET
Suggesting neuroendocrine tumor in nasal cavity
Normal hot uptake of pituitary grand
Whole body bone scan No distant metastasis
ACTH, adrenocorticotropic hormone; DMST, dexamethasone suppression test; IPSS, inferior petrosal sinus sampling; MRI, magnetic resonance imaging; PET, posi-
tron emission tomography.
Fig. 2. High-power view of H&E staining shows small- to medium-sized neoplastic cells with lobulation. Necrosis and mitosis are not seen. Immunohisto-
chemistry (IHC) staining for various cell markers revealed positive staining for adrenocorticotropic hormone (ACTH), neuron-specific enolase (NSE), and 








Esthesioneuroblastoma is a rare sinonasal tumor, that can ex-
tend to the paranasal sinuses, orbital cavity, and anterior cra-
nial fossa.3 Ectopic ACTH syndrome comprises 5–20% of Cush-
ing’s syndrome.1,4 Esthesioneuroblastoma as a hormone-
secreting tissue was first identified in 1967 as a syndrome of 
inappropriate antidiuretic hormone presentation,5 and ACTH-
secreting esthesioneuroblastoma was first described in 1987.6
Endocrinological workup to diagnose Cushing’s disease in-
cludes low- and high-dose DMST, IPSS, and corticotropin re-
leasing hormone stimulation test. When IPPSS is suggestive of 
pituitary ACTH secretion and MRI fails to localize a tumor in a 
sellar region, a dilemma arises as to whether to seek an explor-
ative operation or not. In our case, 68Ga-DOTA-conjugated PET 
greatly helped in localizing the source of ACTH secretion in 
the nasal cavity and not performing unnecessary pituitary sur-
gery. In fact, if an ectopic ACTH source is located upstream of 
the pituitary gland, as with, for example, an ethmoid sinus tu-
mor, petrosal venous ACTH levels may be increased, and thus 
IPSS can be false positive.7-9
Because somatostatin receptor expression is a distinctive 
characteristic of neuroendocrine tumors, 18F-FDG PET or oc-
treotide scintigraphy has been utilized in detecting esthesio-
neuroblastoma.10 However, 68Ga-DOTA-congugated octreotide 
PET scan shows greater sensitivity and specificity than con-
ventional 18F-FDG PET or octreotide scan.11,12 In our case, where 
the results of diagnostic tests were discordant, 68Ga-DOTA-
conjugated PET clearly demonstrated that the source of ACTH 
secretion was not the pituitary gland, but a tumor in the nasal 
cavity. This is the first report to utilize 68Ga-DOTA-conjugated 
PET to diagnosis undetected ACTH-secreting esthesioneuro-
blastoma.
The endoscopic endonasal approach provides great acces-
sibility and visibility without extensive destruction of the cra-
niofacial vault.13 However, in this case, because the tumor had 
invaded multiple paranasal sinuses and the anterior skull base, 
as well as part of the frontal lobe (Kadish stage C), we accessed 
the tumor with combined endonasal and transcranial ap-
proaches. A high likelihood of local recurrence in the Kadish 
stage C tumor necessitated adjuvant radiotherapy after the 
surgery. Some have advocated the usefulness of chemothera-
py, especially in the case of cervical metastasis or high histo-
logical grade (Hyams grade III or IV).14 Because the histologi-
cal grade of the tumor in this case was Hyams grade I and 
radical tumor removal was achieved, the patient did not un-
dergo chemotherapy.
Without question, careful surveillance is mandatory in ad-
vanced esthesioneuroblastoma. Not only regular MRI check-
up, but also 68Ga-DOTA-conjugated PET is useful for surveil-
lance.2 Furthermore, measuring serum cortisol and plasma 
ACTH directly provides helpful information. Kanno, et al.7 has 
proposed that measurement of tumor-associated hormones 
is important for surveillance. Despite the potential for some 
unforeseen difficulties, we emphasize that using 68Ga-DOTA-
conjugated PET and monitoring ACTH and cortisol levels com-
prise a reliable and convenient way through which to check for 
recurrence in ectopic ACTH-secreting esthesioneuroblastoma.
SUPPLEMENTARY DATA
Video 1. Removal of intranasal part of the tumor under endo-
scopic endonasal approach. Intranasal part of the tumor was 
approached under endoscopic visualization. After identifica-
tion of the tumor, en bloc resection was attempted rather than 
piecemeal resection. As the tumor showed high vascularity, 
meticulous coagulation and cutting was repeated along the at-
tachment to the nasal roof antero-posteriorly. Finally, the tu-
mor mass was separated from the nasal roof and the entire in-
tranasal part of the tumor was removed in one piece.
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